Investigating the longitudinal association between diabetes and anxiety: a systematic review and meta-analysis by Smith, Kimberley et al.
Systematic Review or Meta-analysis
Investigating the longitudinal association between
diabetes and anxiety: a systematic review and meta-
analysis
K. J. Smith1 , S. S. Desche^nes2,3 and N. Schmitz2,3,4,5
1Department of Psychological Sciences, University of Surrey, Guildford, UK, 2Douglas Mental Health University Institute, 3Department of Psychiatry, 4Department
of Epidemiology and Biostatistics, McGill University and 5Montreal Diabetes Research Center, Montreal, Canada
Accepted 16 February 2018
Abstract
Aim Previous research has indicated an association between diabetes and anxiety. However, no synthesis has
determined the direction of this association. The aim of this study was to determine the longitudinal relationship
between anxiety and diabetes.
Methods We searched seven databases for studies examining the longitudinal relationship between anxiety and
diabetes. Two independent reviewers screened studies from a population aged 16 or older that examined either anxiety
as a risk factor for incident diabetes or diabetes as a risk factor for incident anxiety. Studies that met eligibility criteria
were put forward for data extraction and meta-analysis.
Results In total 14 studies (n = 1 760 800) that examined anxiety as a risk factor for incident diabetes and two
(n = 88 109) that examined diabetes as a risk factor for incident anxiety were eligible for inclusion in the review. Only
studies examining anxiety as a risk factor for incident diabetes were put forward for the meta-analysis. The least adjusted
(unadjusted or adjusted for age only) estimate indicated a significant association between baseline anxiety with incident
diabetes (odds ratio 1.47, 1.23–1.75). Furthermore, most-adjusted analyses indicated a significant association between
baseline anxiety and incident diabetes. Included studies that examined diabetes to incident anxiety found no association.
Conclusions There was an association between baseline anxiety and incident diabetes. The results also indicate the need
for more research to examine the direction of association from diabetes to incident anxiety. This work adds to the
growing body of evidence that poor mental health increases the risk of developing diabetes.
Diabet. Med. 00: 000–000 (2018)
Introduction
The prevalence of diabetes is increasing, with current
estimates projecting that 642 million people worldwide will
have diabetes by 2040 [1]. As the prevalence of diabetes
increases there is interest in identifying modifiable diabetes
risk factors that could be targeted by interventions to reduce
this projected increase. Alongside this, there is also interest in
reducing the burden of diabetes in people who already have
the condition by identifying modifiable risk factors associ-
ated with poorer health outcomes. Poor mental health has
been identified as a potentially modifiable risk factor
associated with an increased risk of both developing diabetes
and poorer outcomes in people who have diabetes [2,3].
Therefore, there is interest in how mental illness and diabetes
are linked.
Anxiety disorders are a group of mental disorders charac-
terized by feelings of anxiety and fear that significantly
impact the social and occupational functioning of individuals
[4]. They are among some of the most prevalent mental
disorders in the population, affecting up to 30% of adults
[5,6]. Furthermore, anxiety disorders are one of the leading
causes of disability worldwide [7] and are associated with a
poorer quality of life [8]. Alongside their immediate impact
on mental health and functioning, there is also evidence that
symptoms of anxiety and anxiety disorders might be asso-
ciated with an increased risk of developing non-communic-
able diseases such as heart disease [9]. It is possible that
anxiety could lead to diabetes as it shares strong associations
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with many of the acknowledged risk factors for diabetes such
as overweight/obesity [10], cardiometabolic abnormalities
[11], unhealthy lifestyle behaviours [12] and sleep distur-
bance [13]. However, data on anxiety as a risk factor for
incident diabetes has not yet been synthesized, so it is unclear
whether anxiety itself is an independent risk factor for the
development of diabetes.
Previous research indicates that people with diabetes have a
greater likelihood of developing mental health problems such
as depression [14]. It is possible that biological changes
induced by diabetes [15] alongside lifestyle limitations and
feelings related to living with a serious chronic illness [16]
could all be linked with poorer mental health. However, there
is no synthesis that tells us whether diabetes might be linked
with a greater risk of developing anxiety. Previous meta-
analyses and systematic reviews indicate that people with
diabetes have an increased likelihood of concurrent anxiety
[17,18], however we do not know if diabetes is associated
with an increased risk of developing incident anxiety.
The aim of this review was to determine the longitudinal
association between diabetes and anxiety by systematically
searching for and reviewing studies that investigated either
anxiety as a risk factor for incident diabetes in adults aged 16
or older or diabetes as a risk factor for incident anxiety in
adults aged 16 or older.
Methods
Search strategy
A systematic literature search was conducted by KS and SD
between January 2017 and August 2017. The study protocol
was registered on PROSPERO (protocol ID: CRD420170
56775; https://www.crd.york.ac.uk/PROSPERO).There were
no restrictions on publication date or language, although only
English and French language studies were reviewed. Search
terms relating to synonyms of ‘anxiety’ and ‘diabetes’ (see Doc.
S1) were searched in seven databases including PubMed
(United States National Library of Medicine, Bethesda, MD,
USA), SCOPUS (Elsevier, Amsterdam, Netherlands), EMBASE
(Elsevier), ISI Web of Knowledge (Thomson Reuters, New
York, NY, USA), PsychINFO (American Psychological
Association, Washington DC, USA), CINAHL (Elsevier) and
ProQuest (Dissertations and Theses; conference papers index
and Nursing and Allied Health) (ProQuest, Ann Arbour, MI,
USA).
Further to this, hand searches were undertaken within
relevant conference proceedings and journals (see Supporting
Information Doc. S1). The bibliographies of relevant reviews
on anxiety and diabetes [17–19] were also searched.
Study selection
For the direction of anxiety to incident diabetes, eligible
studies were prospective studies that assessed the incidence of
diabetes in people aged 16 or over who were assessed for the
presence of anxiety at baseline. To examine diabetes to
incident anxiety, studies were required to be prospective
studies that assessed the incidence of anxiety in people aged
16 or over who were assessed for the presence of diabetes at
baseline. Only studies that examined Type 1 and/or Type 2
diabetes were included. Included studies were required to
assess anxiety symptoms (as defined by elevated anxiety
symptoms on a validated scale) or anxiety disorders (as
assessed by diagnostic interview or clinical diagnosis). In this
review, anxiety was defined as the anxiety disorders included
in Diagnostic and Statistical Manual (DSM) version IV or V;
version V excludes post-traumatic stress disorder (PTSD) and
obsessive–compulsive disorder (OCD) whereas version IV
includes these disorders. For both research questions, exclu-
sion criteria included a cross-sectional study design, studies
that did not assess incidence (i.e. did not control for baseline
levels of the outcome) and those that explicitly assessed
gestational diabetes. There were no restrictions set on the
type of population included.
Two authors (KS and SD) independently screened all
studies for these criteria (see Fig. 1), and disagreements were
resolved by consensus or, where necessary, a third author
(NS). Studies that were shortlisted after full-text assessment
were put forward for data extraction and quality assessment.
Data extraction and quality assessment
Data extraction and quality assessment were completed
independently by two authors (KS and SD) with disagree-
ments resolved by consensus. The following characteristics
were extracted from eligible studies: author (date), study
characteristics (name, country, number of participants),
sample characteristics (% female, ethnicity and age), anxiety
measurement (name of measure, information regarding type
of anxiety assessed), diabetes measurement, outcome infor-
mation (follow-up length, % developed outcome), statistical
analysis (type of statistical test and confounders controlled
for) and measures of association (unadjusted and/or most-
adjusted estimate).
Quality assessment was performed using two tools: the
Newcastle–Ottawa Scale (NOS) [20] and the Risk Of Bias In
What’s new?
• This is the first synthesis to determine the direction of
association between anxiety and diabetes.
• The results indicate that anxiety is a risk factor for
incident diabetes.
• The results also indicate that there is a need for further
research into diabetes as a risk factor for incident
anxiety.
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Non-randomized Studies of Interventions (ROBINS-I) [21].
We opted to use both tools because the NOS offers a good
overview of study methodology and representativeness,
whereas the ROBINS-I offers a more comprehensive assess-
ment of bias. The following characteristics were assessed
using the NOS: representativeness of sample (community
sample), selection of controls (same population as sample),
measure of predictor and outcome (validated measurements),
demonstration that outcome not present at start of study,
length of follow-up (≥ 5 years), adequacy of follow-up
participation rate (> 60%), inclusion of at least three
important confounders and if the study controlled for the
most important confounder (metabolic abnormalities). Stud-
ies were assessed on a star system whereby they were given
one star for each criterion met. Possible scores ranged from
0 to 9, with higher scores being indicative of better study
quality. See Table S1 for NOS quality assessment.
Use of the ROBINS-I requires pre-identification of the
most important confounders to assess bias. For the present
review assessing the direction of anxiety to diabetes, the most
important confounders were determined to be sociodemo-
graphic characteristics (e.g. age, sex, ethnicity, education,
income) and cardiometabolic abnormalities (e.g. adiposity,
blood pressure, inflammation, cholesterol, triglycerides). For
the direction of diabetes to anxiety, the most important
confounders were determined to be sociodemographic char-
acteristics and other chronic conditions. Choice of con-
founders was based on these variables sharing a potentially
explanatory association between the relevant predictor and
outcome [10,11,18]. The ROBINS-I assessed studies on the
following characteristics: bias due to confounding, bias in
selection of participants into study, bias due to deviations
from intended interventions, bias due to missing data, bias in
measurement of outcomes and bias in selection of the
reported result. Following the assessment of bias in each
domain the authors independently judged the overall risk of
bias as: critical, serious, moderate or low. See Table S2 for
the ROBINS-I quality assessment.
In addition to the quantitative quality assessments, both
screening authors also undertook a qualitative quality
assessment to independently determine the main strengths
and limitations of each included study.
Meta-analysis
Eligible data were entered into a random-effects meta-
analysis because this provides more conservative estimates
allowing for more heterogeneity between studies. If studies
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provided stratified analyses for their predictor (e.g. analyses
stratified by gender) these were first combined into a single
estimate. We then plotted the least adjusted (unadjusted or
adjusted for age only) association, followed by the most
adjusted. For the least adjusted association, we either used
odds ratios (ORs; unadjusted or adjusted for age only) or
calculated the OR using raw event data. For each associa-
tion, we performed a series of sensitivity analyses to assess
the impact of methodological study differences (e.g. popu-
lation studied, confounders controlled for, anxiety assess-
ment) on the strength of the associations.
Alongside the meta-analyses we determined statistical
heterogeneity for each analysis by calculating the inconsis-
tency (I2) index (scores of 25%, 50% and 75% indicate
low, moderate and high heterogeneity, respectively). Publi-
cation bias was assessed by visual inspection of funnel plots
and Egger’s test, with symmetric funnel plots and a non-
significant Egger’s test being indicative of no publication
bias. All analyses were performed with Comprehensive
Meta-Analysis 3.0 (Biostat, Englewood, NJ, USA).
Results
Study selection
In total, 5418 studies were found after excluding duplicates
(Fig. 1). After applying broad screening criteria, 5295 studies
were excluded. The main reasons for excluding studies were
that they did not assess the predictor or outcome of interest,
the study was conducted in a non-human population,
language restrictions or that the study was cross-sectional.
A total of 124 studies were put forward for full-text analysis,
following which 108 were excluded. Reasons for exclusion
were that the study did not assess incidence of diabetes or
anxiety, the study was a poster presentation with no full-text
access for data extraction, the study was cross-sectional and
the study did not perform the analysis required for inclusion
in this review. Inter-rater reliability for study screening was
good (kappa = 0.72).
Of the remaining 16 studies, 14 examined the direction of
association from anxiety to incident diabetes and two
examined the direction of association from diabetes to
incident anxiety. Table 1 summarizes the characteristics of
the studies. Table 2 summarizes the quality assessments
performed for all studies along with a qualitative synthesis of
the main study strengths and weaknesses as identified by the
reviewers (for the full quality assessment tables see Tables S1
and S2). Most studies (n = 11) were from North America
[22–32], with an additional three studies from Europe [33–
35], one from Asia [36] and one from the Middle-East [37].
Because of the small number of studies examining diabetes
to anxiety (n = 2) we put forward only those studies
examining anxiety to diabetes for the quantitative synthesis
(n = 14).
Study review
Anxiety to incident diabetes
In the 14 studies that examined the association between
anxiety and incident diabetes, 115 418 people from a total of
1 760 800 (6.6%) developed incident diabetes (Table 1).
Seven of the ten studies that provided an unadjusted
or minimally adjusted estimate reported a significant asso-
ciation between baseline anxiety and incident diabetes
[23–25,27,30,31,33]. Of the 13 studies that examined the
most adjusted association between baseline anxiety and
incident diabetes, eight found a significant association
[23,25,27,28,30,31,35,36]. Overall study quality was vari-
able with 10 studies having low or moderate evidence of bias
(see Table 2) and four having some serious bias issues
[26,33,35,37]. In studies identified as having serious bias,
bias was due to issues with adjustment for confounders, lack
of transparency in reporting and participant sampling
(Table 2).
Of the seven studies that found a significant least adjusted
association between baseline anxiety and incident diabetes,
two examined general anxiety symptoms [24,33]. Atlantis
et al. [33] found that for every 10-point increase in the Beck
Anxiety Index score there was a 1.6-fold increase in the odds
of developing incident diabetes over 2 years. However, they
did not provide an adjusted estimate. Demmer et al. [24]
found that in women only, high anxiety symptoms as
measured with the General Well-Being Scale were associated
with a 2.15 times increased likelihood of developing diabetes
over 17 years. However, this association was attenuated
after adjustment for sociodemographics, BMI and lifestyle
characteristics, and no association between anxiety and
diabetes was found in men [24]. A further two studies found
an association between generalized anxiety disorder (GAD)
or GAD symptomatology with incident diabetes [25,31].
Desche^nes et al. [25] stratified their groups based on the
presence of prediabetes and high anxiety symptoms mea-
sured with the GAD-7 scale at baseline. They found that
people with high anxiety and prediabetes had a 10.95 times
increased odds of developing diabetes over 5 years compared
with people with no prediabetes and no anxiety. This
association remained significant after adjustment for a range
of sociodemographic, cardiometabolic, lifestyle and medica-
tion confounders [25]. However, this study also found that
high anxiety symptoms in the absence of prediabetes were
not associated with increased odds of developing diabetes
(Table 1). Scherrer et al. [31], using data from a Veteran’s
database, found that doctor-diagnosed GAD at baseline was
associated with a 1.07 times increased hazard of developing
incident diabetes over 6 years. This association remained
significant after adjustment, however the authors only
adjusted for BMI and age [31].
Of the four studies that examined the association between
PTSD and incident anxiety [23,30–32], three found a
4
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Investigating the longitudinal association between diabetes and anxiety  K. J. Smith et al.
T
a
b
le
1
C
h
a
ra
ct
er
is
ti
cs
o
f
in
cl
u
d
ed
st
u
d
ie
s
A
u
th
o
r,
y
ea
r;
co
u
n
tr
y
S
tu
d
y
B
a
se
li
n
e
sa
m
p
le
A
n
x
ie
ty
m
ea
su
re
m
en
t
D
ia
b
et
es
in
ci
d
en
ce
M
ea
su
re
m
en
t
In
ci
d
en
t
d
ia
b
et
es
ca
se
s
S
ta
ti
st
ic
a
l
a
n
a
ly
si
s
C
o
n
fo
u
n
d
er
s
a
d
ju
st
ed
R
es
u
lt
s
M
ea
su
re
(c
u
t-
o
ff
p
o
in
ts
)
T
y
p
e
o
f
a
n
x
ie
ty
(l
en
g
th
ep
is
o
d
e)
S
o
ci
o
d
em
o
g
ra
p
h
ic
s
C
a
rd
io
-
m
et
a
b
o
li
c
a
n
d
/o
r
a
d
ip
o
si
ty
O
th
er
L
ea
st
a
d
ju
st
ed
M
o
st
a
d
ju
st
ed
A
n
x
ie
ty
to
in
ci
d
en
t
d
ia
b
et
es
A
b
ra
h
a
m
et
al
.,
2
0
1
5
[2
2
];
U
S
A
T
h
e
M
u
lt
i-
E
th
n
ic
S
tu
d
y
o
f
A
th
er
o
sc
le
ro
si
s
(M
E
SA
)
N
=
5
5
6
6
A
g
e:
4
5
–8
5
y
ea
rs
(m
ea
n
6
1
.6
y
ea
rs
)
S
ex
:
5
3
.2
%
fe
m
a
le
E
th
n
ic
it
y
:
3
8
%
w
h
it
e,
2
8
%
A
fr
ic
a
n
A
m
er
ic
a
n
,
2
3
%
H
is
p
an
ic
,
1
1
%
C
h
in
es
e
S
p
ie
lb
er
g
er
T
ra
it
A
n
x
ie
ty
S
ca
le
.
(Q
u
a
rt
il
es
Q
1
<
1
3
;
Q
2
=
1
3
–1
5
;
Q
3
=
1
6
–1
9
;
Q
4
=
2
0
–4
0
)
T
ra
it
a
n
x
ie
ty
(c
u
rr
en
t)
F
a
st
in
g
g
lu
co
se
≥
m
m
o
l/
l
(1
2
6
m
g
/d
l)
,
u
se
o
f
o
ra
l
h
y
p
o
g
ly
ca
em
ic
m
ed
ic
a
ti
o
n
a
n
d
/o
r
in
su
li
n
,
o
r
se
lf
-
re
p
o
rt
ed
p
h
ys
ic
ia
n
d
ia
g
n
o
si
s
6
9
5
(1
2
.4
%
)
F
o
ll
o
w
-u
p
:
1
1
.4
y
ea
rs
C
o
x
p
ro
p
o
rt
io
n
a
l
h
a
za
rd
s
re
g
re
ss
io
n
(r
ef
er
en
ce
g
ro
u
p
:
Q
1
)
S
ex
,
a
g
e,
ra
ce
/
et
h
n
ic
it
y
,
y
ea
rs
o
f
ed
u
ca
ti
o
n
,
a
n
n
u
al
in
co
m
e
W
a
is
t
ci
rc
u
m
fe
re
n
ce
,
b
lo
o
d
p
re
ss
u
re
,
C
-r
ea
ct
iv
e
p
ro
te
in
.
D
ep
re
ss
iv
e
sy
m
p
to
m
s,
a
n
ti
d
ep
re
ss
a
n
ts
,
d
ie
t,
sm
o
k
in
g
,
a
lc
o
h
o
l
u
se
,
in
te
rl
eu
k
in
-6
Q
2
:
H
R
1
.0
2
(0
.8
3
–1
.2
6
)
Q
3
:
H
R
0
.9
9
(0
.8
0
–1
.2
3
)
Q
4
:
H
R
1
.1
6
(0
.9
3
–1
.4
5
)
Q
2
:
H
R
0
.9
8
(0
.7
8
–1
.2
3
)
Q
3
:
H
R
0
.9
9
(0
.7
8
–1
.2
6
)
Q
4
:
H
R
1
.1
6
(0
.8
7
–1
.5
4
)
A
tl
a
n
ti
s
et
al
,
2
0
1
3
[3
3
];
T
h
e
N
et
h
er
la
n
d
s
N
et
h
er
la
n
d
s
S
tu
d
y
o
f
D
ep
re
ss
io
n
a
n
d
A
n
x
ie
ty
(N
E
S
D
A
)
N
=
2
4
6
0
A
g
e:
1
8
–6
5
y
ea
rs
(m
ea
n
4
2
)
S
ex
:
6
6
%
fe
m
a
le
E
th
n
ic
it
y
:
n
o
t
sp
ec
ifi
ed
(A
)
2
1
-i
te
m
B
ec
k
A
n
x
ie
ty
In
v
en
to
ry
(B
)
C
o
m
p
o
si
te
In
te
rn
a
ti
o
n
a
l
D
ia
g
n
o
st
ic
In
te
rv
ie
w
(C
ID
I)
(A
)
A
n
x
ie
ty
sy
m
p
to
m
se
v
er
it
y
(p
a
st
m
o
n
th
)
(B
)
A
n
x
ie
ty
d
is
o
rd
er
:
S
o
ci
a
l
p
h
o
b
ia
,
g
en
er
a
li
ze
d
a
n
x
ie
ty
d
is
o
rd
er
,
p
a
n
ic
d
is
o
rd
er
a
n
d
/o
r
a
g
o
ra
p
h
o
b
ia
(6
-m
o
n
th
)
S
el
f-
re
p
o
rt
fo
r
li
fe
ti
m
e
d
ia
g
n
o
si
s,
a
n
ti
-d
ia
b
et
ic
m
ed
ic
a
ti
o
n
u
se
,
o
r
fa
st
in
g
p
la
sm
a
g
lu
co
se
≥
7
.0
m
m
o
l/
l
2
5
in
ci
d
en
t
d
ia
b
et
es
ca
se
s
(1
.3
%
)
F
o
ll
o
w
-u
p
:
2
y
ea
rs
L
o
g
is
ti
c
re
g
re
ss
io
n
(p
re
d
ic
to
r=
ev
er
y
1
0
-p
o
in
t
in
cr
ea
se
B
A
I)
–
–
–
O
R
1
.6
(1
.2
–2
.1
)
–
B
o
y
k
o
et
al
,
2
0
1
0
[2
3
];
U
S
A
M
il
le
n
n
iu
m
C
o
h
o
rt
S
tu
d
y
N
=
4
4
7
5
4
A
g
e:
1
8
–6
8
y
ea
rs
(m
ed
ia
n
3
6
y
ea
rs
)
N
o
in
ci
d
en
t
d
ia
b
et
es
S
ex
:
2
6
.4
%
fe
m
a
le
E
th
n
ic
it
y
:
7
1
.8
%
C
a
u
ca
si
a
n
1
1
.6
%
A
fr
ic
a
n
A
m
er
ic
a
n
5
.8
%
H
is
p
a
n
ic
8
.6
%
A
si
a
n
2
.2
%
o
th
er
In
ci
d
en
t
d
ia
b
et
es
S
ex
:
2
7
.7
%
fe
m
a
le
E
th
n
ic
it
y
:
6
5
.2
%
C
a
u
ca
si
a
n
1
8
.9
%
A
fr
ic
a
n
A
m
er
ic
a
n
6
.3
%
H
is
p
a
n
ic
P
T
SD
:
1
7
-i
te
m
P
C
L
-C
(m
o
d
er
at
e
o
r
h
ig
h
er
le
v
el
o
n
e
in
tr
u
si
o
n
sy
m
p
to
m
,
th
re
e
a
v
o
id
a
n
ce
sy
m
p
to
m
s,
a
n
d
tw
o
h
y
p
er
a
ro
u
sa
l
sy
m
p
to
m
s)
P
a
n
ic
:
P
H
Q
(e
n
d
o
rs
ed
ei
g
h
t
it
em
s
a
sk
in
g
a
b
o
u
t
w
h
et
h
er
h
a
d
p
a
n
ic
a
tt
ac
k
s
a
n
d
co
g
n
it
io
n
s
a
b
o
u
t
p
a
n
ic
a
tt
ac
k
)
O
th
er
a
n
x
ie
ty
:
P
H
Q
(e
n
d
o
rs
ed
it
em
,
a
sk
in
g
a
b
o
u
t
P
T
SD
sy
m
p
to
m
s
(p
a
st
m
o
n
th
)
P
a
n
ic
d
is
o
rd
er
sy
m
p
to
m
s
(2
w
ee
k
s)
O
th
er
a
n
x
ie
ty
sy
m
p
to
m
s
(2
w
ee
k
s)
S
el
f-
re
p
o
rt
3
7
6
in
ci
d
en
t
d
ia
b
et
es
ca
se
s
(0
.0
1
%
)
F
o
ll
o
w
-u
p
:
3
y
ea
rs
L
o
g
is
ti
c
re
g
re
ss
io
n
A
g
e,
se
x
,
et
h
n
ic
it
y
,
ed
u
ca
ti
o
n
a
l
a
tt
a
in
m
en
t
B
M
I
–
P
T
SD
O
R
2
.5
6
(1
.7
8
–3
.6
7
)
P
an
ic
d
is
o
rd
er
O
R
3
.1
9
(1
.7
8
–5
.7
1
)
O
th
er
an
x
ie
ty
O
R
2
.0
3
(1
.1
6
–3
.5
4
)
P
T
SD
O
R
2
.2
4
(1
.5
4
–3
.2
6
)
P
an
ic
d
is
o
rd
er
:
O
R
2
.8
8
(1
.5
8
–5
.2
4
)
O
th
er
an
x
ie
ty
O
R
1
.7
7
(1
.0
0
–3
.1
3
)
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 5
Systematic Review or Meta-analysis DIABETICMedicine
T
a
b
le
1
(C
o
n
ti
n
u
ed
)
A
u
th
o
r,
y
ea
r;
co
u
n
tr
y
S
tu
d
y
B
a
se
li
n
e
sa
m
p
le
A
n
x
ie
ty
m
ea
su
re
m
en
t
D
ia
b
et
es
in
ci
d
en
ce
M
ea
su
re
m
en
t
In
ci
d
en
t
d
ia
b
et
es
ca
se
s
S
ta
ti
st
ic
a
l
a
n
a
ly
si
s
C
o
n
fo
u
n
d
er
s
a
d
ju
st
ed
R
es
u
lt
s
M
ea
su
re
(c
u
t-
o
ff
p
o
in
ts
)
T
y
p
e
o
f
a
n
x
ie
ty
(l
en
g
th
ep
is
o
d
e)
S
o
ci
o
d
em
o
g
ra
p
h
ic
s
C
a
rd
io
-
m
et
a
b
o
li
c
a
n
d
/o
r
a
d
ip
o
si
ty
O
th
er
L
ea
st
a
d
ju
st
ed
M
o
st
a
d
ju
st
ed
7
.4
%
A
si
a
n
2
.2
%
o
th
er
fe
el
in
g
n
er
v
o
u
s,
a
n
x
io
u
s,
o
n
ed
g
e,
a
n
d
a
t
le
a
st
th
re
e
o
f
si
x
a
d
d
it
io
n
a
l
a
n
x
ie
ty
sy
m
p
to
m
s)
C
h
ie
n
&
L
in
,
2
0
1
6
[3
6
];
T
a
iw
a
n
T
a
iw
a
n
N
a
ti
o
n
a
l
H
ea
lt
h
In
su
ra
n
ce
(N
H
I)
p
ro
g
ra
m
N
=
7
6
6
4
2
7
A
g
e:
1
8
+
y
ea
rs
(m
ea
n
n
o
t
sp
ec
ifi
ed
)
A
n
x
ie
ty
gr
o
u
p
S
ex
:
1
1
.8
8
%
fe
m
a
le
C
o
n
tr
o
l
gr
o
u
p
S
ex
:
5
.7
7
%
fe
m
a
le
IC
D
-9
-C
M
d
ia
g
n
o
st
ic
co
d
es
(a
t
le
a
st
tw
o
se
rv
ic
e
cl
a
im
s
d
u
ri
n
g
2
0
0
5
fo
r
ei
th
er
o
u
tp
a
ti
en
t
o
r
in
p
a
ti
en
t
ca
re
)
A
n
x
ie
ty
st
a
te
s,
p
a
n
ic
d
is
o
rd
er
,
g
en
er
a
li
ze
a
n
x
ie
ty
d
is
o
rd
er
,
p
h
o
b
ic
d
is
o
rd
er
,
o
b
se
ss
iv
e-
co
m
p
u
ls
iv
e
d
is
o
rd
er
,
a
cu
te
st
re
ss
d
is
o
rd
er
,
a
n
d
p
o
st
-
tr
a
u
m
a
ti
c
st
re
ss
d
is
o
rd
er
(p
a
st
y
ea
r)
A
t
le
a
st
o
n
e
p
re
sc
ri
p
ti
o
n
(o
ra
l
h
y
p
o
g
ly
ca
em
ic
a
g
en
ts
o
r
in
su
li
n
)
fo
r
tr
ea
tm
en
t
o
f
d
ia
b
et
es
3
7
0
3
2
in
ci
d
en
t
ca
se
s
F
o
ll
o
w
-u
p
:
5
y
ea
rs
C
o
x
re
g
re
ss
io
n
m
o
d
el
A
g
e,
se
x
,
in
su
ra
n
ce
a
m
o
u
n
t,
re
g
io
n
,
a
n
d
u
rb
a
n
ic
it
y
–
–
–
R
R
1
.3
4
(1
.2
8
–1
.4
1
)
D
em
m
er
et
al
.,
2
0
1
5
[2
4
];
U
S
A
F
ir
st
N
a
ti
o
n
a
l
H
ea
lt
h
a
n
d
N
u
tr
it
io
n
E
x
a
m
in
a
ti
o
n
S
u
rv
ey
(N
H
A
N
E
S
I)
a
n
d
it
s
ep
id
em
io
lo
g
ic
a
l
fo
ll
o
w
-u
p
st
u
d
y
(N
H
E
F
S
)
N
=
3
2
3
3
A
g
e:
2
5
–7
4
y
ea
rs
(m
ea
n
4
9

1
4
y
ea
rs
)
S
ex
:
2
%
fe
m
a
le
E
th
n
ic
it
y
:
8
6
%
w
h
it
e
1
4
%
A
fr
ic
a
n
A
m
er
ic
a
n
G
en
er
a
l
W
el
lb
ei
n
g
S
ca
le
:
A
n
x
ie
ty
su
b
sc
a
le
(G
W
B
-A
):
h
ig
h
(0
–1
2
),
m
o
d
er
a
te
(1
3
–1
8
),
lo
w
(1
9
–2
5
)
A
n
x
ie
ty
sy
m
p
to
m
s
(p
a
st
m
o
n
th
)
(A
)
D
ea
th
ce
rt
ifi
ca
te
IC
D
-9
co
d
e
sp
ec
ifi
es
d
ia
b
et
es
(B
)
S
el
f-
re
p
o
rt
ed
p
h
ys
ic
ia
n
d
ia
g
n
o
si
s
re
q
u
ir
in
g
m
ed
ic
a
ti
o
n
(C
)
H
ea
lt
h
ca
re
fa
ci
li
ty
st
a
y
w
it
h
d
ia
b
et
es
d
is
ch
a
rg
e
d
ia
g
n
o
si
s.
2
9
8
in
ci
d
en
t
ca
se
s
(9
.2
%
)
F
o
ll
o
w
-u
p
:
1
7
y
ea
rs
(A
)
M
u
lt
i-
v
a
ri
a
b
le
a
d
ju
st
ed
ri
sk
ra
ti
o
s
fr
o
m
fi
tt
ed
lo
g
is
ti
c
re
g
re
ss
io
n
m
o
d
el
s
A
g
e,
ra
ce
,
ed
u
ca
ti
o
n
,
B
M
I
S
m
o
k
in
g
st
a
tu
s,
a
n
d
p
h
y
si
ca
l
a
ct
iv
it
y
M
o
d
er
at
e
an
x
ie
ty
W
o
m
en
:
R
R
1
.3
3
(0
.7
3
–2
.4
0
)
M
en
:
R
R
0
.8
9
(0
.5
7
–1
.3
8
)
H
ig
h
an
x
ie
ty
W
o
m
en
:
R
R
2
.1
5
(1
.2
4
–3
.7
4
)
M
en
:
R
R
0
.6
8
(0
.3
2
–1
.4
2
)
M
o
d
er
at
e
an
x
ie
ty
W
o
m
en
:
R
R
1
.4
2
(0
.7
8
–2
.6
1
)
M
en
:
R
R
0
.9
4
(0
.6
1
–1
.4
4
)
H
ig
h
an
x
ie
ty
W
o
m
en
:
R
R
1
.7
2
(0
.8
6
–3
.4
4
)
M
en
:
R
R
0
.7
0
(0
.3
2
–1
.5
5
)
D
es
ch
e^n
es
et
al
.,
2
0
1
6
[2
5
];
C
a
n
a
d
a
E
m
o
ti
o
n
a
l
W
el
l-
b
ei
n
g
,
M
et
a
b
o
li
c
F
a
ct
o
rs
a
n
d
H
ea
lt
h
S
ta
tu
s
(E
M
H
S
)
st
u
d
y
N
=
2
4
8
6
A
g
e:
4
0
–6
9
y
ea
rs
S
ex
:
5
7
.4
%
fe
m
a
le
E
th
n
ic
it
y
:
9
3
.3
%
w
h
it
e
6
.7
%
n
o
n
-w
h
it
e
G
en
er
a
li
ze
d
a
n
x
ie
ty
d
is
o
rd
er
q
u
es
ti
o
n
n
a
ir
e
–
7
-i
te
m
(≥
1
0
h
ig
h
a
n
x
ie
ty
)
G
en
er
a
li
ze
d
a
n
x
ie
ty
sy
m
p
to
m
s
(2
w
ee
k
s)
S
el
f-
re
p
o
rt
8
6
in
ci
d
en
t
ca
se
s
(3
.5
%
)
F
o
ll
o
w
-u
p
:
4
.6
y
ea
rs
L
o
g
is
ti
c
re
g
re
ss
io
n
A
g
e,
se
x
,
et
h
n
ic
it
y
,
ed
u
ca
ti
o
n
,
m
a
ri
ta
l
st
a
tu
s
C
en
tr
a
l
o
b
es
it
y
,
h
y
p
er
te
n
si
o
n
,
tr
ig
ly
ce
ri
d
es
,
H
D
L
-
ch
o
le
st
er
o
l
IP
A
Q
sc
o
re
(p
h
y
si
ca
l
a
ct
iv
it
y
),
sm
o
k
in
g
st
a
tu
s,
a
n
ti
d
e-
p
re
ss
a
n
t
u
se
H
ig
h
an
x
ie
ty
n
o
p
re
d
ia
b
et
es
O
R
0
.9
2
(0
.2
1
–4
.0
4
)
H
ig
h
an
x
ie
ty
p
re
d
ia
b
et
es
O
R
1
0
.9
5
(5
.2
4
–2
2
.9
0
)
H
ig
h
an
x
ie
ty
n
o
p
re
d
ia
b
et
es
O
R
1
.1
3
(0
.2
5
–5
.1
0
)
H
ig
h
an
x
ie
ty
p
re
d
ia
b
et
es
O
R
8
.9
5
(3
.5
4
–2
2
.6
3
)
E
d
w
a
rd
s
a
n
d
M
ez
u
k
.,
2
0
1
2
[2
6
];
U
S
A
B
a
lt
im
o
re
E
p
id
em
io
lo
g
ic
C
a
tc
h
m
en
t
A
re
a
S
tu
d
y
N
=
1
4
4
6
A
g
e:
3
0
+
y
ea
rs
S
ex
:
6
8
.5
%
fe
m
a
le
E
th
n
ic
it
y
:
6
3
%
w
h
it
e
3
3
%
b
la
ck
D
ia
g
n
o
st
ic
In
te
rv
ie
w
S
ch
ed
u
le
(D
IS
)
A
n
x
ie
ty
d
is
o
rd
er
s:
g
en
er
a
li
ze
d
a
n
x
ie
ty
d
is
o
rd
er
,
so
ci
a
l
p
h
o
b
ia
,
p
a
n
ic
d
is
o
rd
er
,
a
n
d
a
g
o
ra
-
p
h
o
b
ia
S
el
f-
re
p
o
rt
8
5
in
ci
d
en
t
ca
se
s
(4
.4
%
)
F
o
ll
o
w
-u
p
:
1
1
y
ea
rs
L
o
g
is
ti
c
re
g
re
ss
io
n
A
g
e,
ra
ce
/
et
h
n
ic
it
y
,
ed
u
ca
ti
o
n
,
in
co
m
e,
m
a
ri
ta
l
st
a
tu
s
B
M
I
T
o
b
a
cc
o
u
se
,
p
h
y
si
ca
l
a
ct
iv
it
y
,
a
lc
o
h
o
l
u
se
,
a
n
d
sl
ee
p
in
g
h
a
b
it
s
M
a
jo
r
d
ep
re
ss
iv
e
d
is
o
rd
er
O
R
1
.2
1
(0
.7
2
–2
.0
3
)
O
R
1
.0
0
(0
.5
3
–1
.8
9
)
6
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Investigating the longitudinal association between diabetes and anxiety  K. J. Smith et al.
T
a
b
le
1
(C
o
n
ti
n
u
ed
)
A
u
th
o
r,
y
ea
r;
co
u
n
tr
y
S
tu
d
y
B
a
se
li
n
e
sa
m
p
le
A
n
x
ie
ty
m
ea
su
re
m
en
t
D
ia
b
et
es
in
ci
d
en
ce
M
ea
su
re
m
en
t
In
ci
d
en
t
d
ia
b
et
es
ca
se
s
S
ta
ti
st
ic
a
l
a
n
a
ly
si
s
C
o
n
fo
u
n
d
er
s
a
d
ju
st
ed
R
es
u
lt
s
M
ea
su
re
(c
u
t-
o
ff
p
o
in
ts
)
T
y
p
e
o
f
a
n
x
ie
ty
(l
en
g
th
ep
is
o
d
e)
S
o
ci
o
d
em
o
g
ra
p
h
ic
s
C
a
rd
io
-
m
et
a
b
o
li
c
a
n
d
/o
r
a
d
ip
o
si
ty
O
th
er
L
ea
st
a
d
ju
st
ed
M
o
st
a
d
ju
st
ed
F
a
rv
id
et
al
.,
2
0
1
4
[2
7
];
U
S
A
N
u
rs
es
’
H
ea
lt
h
S
tu
d
y
(N
H
S)
N
=
6
9
3
3
6
N
u
rs
es
’
H
ea
lt
h
S
tu
d
y
II
(N
H
S
II
)
N
=
8
0
1
2
0
H
ea
lt
h
P
ro
fe
ss
io
n
a
l’
s
F
o
ll
o
w
-U
p
S
tu
d
y
(H
P
F
S
)
N
=
3
0
8
3
0
N
H
S
A
g
e
3
0
–5
5
y
ea
rs
,
S
ex
:
1
0
0
%
fe
m
a
le
N
H
S
II
A
g
e
2
4
–4
3
y
ea
rs
S
ex
:
1
0
0
%
fe
m
a
le
H
P
F
S
A
g
e
4
0
–7
5
y
ea
rs
S
ex
:
0
%
fe
m
a
le
E
th
n
ic
it
y
a
ll
st
u
d
ie
s:
~
9
8
%
w
h
it
e
(A
)
C
ro
w
n
-
C
ri
sp
in
d
ex
(C
C
I)
(C
o
n
ti
n
u
o
u
s)
(B
)
C
C
I
≥
6
v
s.
≤
2
P
h
o
b
ic
a
n
x
ie
ty
(c
u
rr
en
t)
Q
u
es
ti
o
n
n
a
ir
e:
(A
)
O
n
e
o
r
m
o
re
cl
a
ss
ic
sy
m
p
to
m
(e
x
ce
ss
iv
e
th
ir
st
,
p
o
ly
u
ri
a
,
w
ei
g
h
t
lo
ss
,
h
u
n
g
er
)
p
lu
s
fa
st
in
g
p
la
sm
a
g
lu
co
se
≥
1
4
0
m
g
/d
l
o
r
ra
n
d
o
m
p
la
sm
a
g
lu
co
se
≥
2
0
0
m
g
/d
l
(B
)
≥
2
el
ev
a
te
d
p
la
sm
a
g
lu
co
se
co
n
ce
n
tr
a
ti
o
n
s
o
n
d
if
fe
re
n
t
o
cc
a
si
o
n
s
(f
a
st
in
g
co
n
ce
n
tr
a
ti
o
n
s
≥
1
4
0
m
g
/d
l,
ra
n
d
o
m
p
la
sm
a
g
lu
co
se
≥
2
0
0
m
g
/d
l
a
n
d
/o
r
co
n
ce
n
tr
a
ti
o
n
s
g
lu
co
se
≥
2
0
0
m
g
/d
l
a
ft
er
2
-h
O
G
T
T
.
N
.B
.
F
o
r
ca
se
s
d
ia
g
n
o
se
d
o
n
/a
ft
er
1
9
9
8
fa
st
in
g
g
lu
co
se
≥
1
2
6
m
g
/d
l.
N
H
S
6
1
8
0
in
ci
d
en
t
ca
se
s
F
o
ll
o
w
-u
p
:
2
0
y
ea
rs
N
H
S
II
4
4
0
1
in
ci
d
en
t
ca
se
s
F
o
ll
o
w
-u
p
:
1
8
y
ea
rs
H
P
F
S
2
2
9
5
in
ci
d
en
t
ca
se
s
F
o
ll
o
w
-u
p
:
2
0
y
ea
rs
N
.B
.:
F
o
r
H
P
F
S
in
ci
d
en
t
ca
se
s
re
p
o
rt
ed
a
s
2
3
0
4
,
b
u
t
a
cc
o
rd
in
g
to
ta
b
le
it
is
2
2
9
5
C
o
x
p
ro
p
o
rt
io
n
a
l
h
a
za
rd
s
m
o
d
el
s
A
g
e,
ra
ce
,
m
a
ri
ta
l
st
a
tu
s,
h
u
sb
an
d
ed
u
ca
ti
o
n
(i
n
N
H
S
a
n
d
N
H
S
II
).
B
M
I
F
a
m
il
y
h
is
to
ry
o
f
d
ia
b
et
es
,
cu
rr
en
t
a
sp
ir
in
u
se
,
m
en
o
p
a
u
sa
l
st
a
tu
s
a
n
d
h
o
rm
o
n
e
u
se
(i
n
N
H
S
a
n
d
N
H
S
II
),
sm
o
k
in
g
st
a
tu
s,
a
lc
o
h
o
l
in
ta
k
e,
p
h
ys
ic
a
l
a
ct
iv
it
y
,
en
er
g
y
in
ta
k
e,
d
ie
ta
ry
sc
o
re
,
co
ff
ee
(A
)
N
H
S
H
R
1
.0
6
(1
.0
5
–1
.0
7
)
N
H
S
II
H
R
1
.1
1
(1
.0
9
–1
.1
2
)
H
P
F
S
H
R
1
.0
4
(1
.0
2
–1
.0
6
)
(B
)
N
H
S
H
R
1
.0
6
(1
.0
5
–1
.0
7
)
N
H
S
II
H
R
1
.1
1
(1
.0
9
–1
.1
2
)
H
P
F
S
H
R
1
.0
4
(1
.0
2
–1
.0
6
)
N
.B
.
a
g
e
a
d
ju
st
ed
(A
)
N
H
S
H
R
1
.0
3
(1
.0
2
–1
.0
4
)
N
H
S
II
H
R
1
.0
4
(1
.0
3
–1
.0
5
)
H
P
F
S
H
R
0
.9
9
(0
.9
7
–1
.0
1
)
(B
)
N
H
S
H
R
1
.1
3
(1
.0
5
–1
.2
2
)
N
H
S
II
H
R
1
.2
9
(1
.1
8
–1
.4
2
)
H
P
F
S
H
R
0
.9
0
(0
.7
5
–1
.0
1
)
K
h
a
m
b
a
ty
et
al
.,
2
0
1
7
[2
8
];
U
S
A
Im
p
ro
v
in
g
M
o
o
d
-
P
ro
m
o
ti
n
g
A
cc
es
s
to
C
o
ll
a
b
o
ra
ti
v
e
T
re
a
tm
en
t
(I
M
P
A
C
T
)
tr
ia
l
N
=
2
1
5
6
A
g
e:
6
0
+
y
ea
rs
(m
ea
n
6
9
.0

7
.3
y
ea
rs
)
S
ex
:
6
8
.9
%
fe
m
a
le
E
th
n
ic
it
y
:
5
3
.3
%
A
fr
ic
an
A
m
er
ic
a
n
P
H
Q
-2
(n
er
v
es
o
r
fe
el
in
g
a
n
x
io
u
s
o
r
o
n
ed
g
e,
w
o
rr
y
in
g
a
b
o
u
t
a
lo
t
o
f
d
if
fe
re
n
t
th
in
g
s)
.
A
n
x
ie
ty
:
en
d
o
rs
ed
b
o
th
sc
re
en
in
g
it
em
s.
A
n
x
ie
ty
sy
m
p
to
m
s
(p
a
st
m
o
n
th
)
M
ed
ic
al
re
co
rd
s
a
n
d
in
su
ra
n
ce
d
a
ta
b
a
se
:
(I
C
D
-9
co
d
e
2
5
0
),
fa
st
in
g
g
lu
co
se
o
f
≥
1
2
6
m
g
/d
l,
H
b
A
1
c
o
f
≥
8
.0
%
,
p
re
sc
ri
p
ti
o
n
fo
r
in
su
li
n
o
r
o
ra
l
h
y
p
o
g
ly
ca
em
ic
m
ed
ic
a
ti
o
n
,
o
r
d
ea
th
d
u
e
to
d
ia
b
et
es
m
el
li
tu
s
(I
C
D
-1
0
co
d
es
E
1
0
-E
1
4
a
s
fi
rs
t-
li
st
ed
ca
u
se
o
f
d
ea
th
).
5
5
8
in
ci
d
en
t
ca
se
s
(2
5
.9
%
)
F
o
ll
o
w
-u
p
:
1
0
y
ea
rs
C
o
x
p
ro
p
o
rt
io
n
a
l
h
a
za
rd
s
m
o
d
el
s
A
g
e,
se
x
,
ra
ce
B
M
I,
h
y
p
er
te
n
si
o
n
,
h
y
p
er
ch
o
-
le
st
er
o
la
em
ia
S
m
o
k
in
g
.
–
A
n
x
ie
ty
(e
it
h
er
it
em
)
H
R
1
.3
6
(1
.1
5
–1
.6
1
)
F
ee
li
n
g
an
x
io
u
s
it
em
H
R
1
.2
6
(1
.0
6
–1
.5
1
)
W
o
rr
y
it
em
H
R
1
.2
8
(1
.0
7
–1
.5
2
)
S
el
f-
re
p
o
rt
–
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 7
Systematic Review or Meta-analysis DIABETICMedicine
T
a
b
le
1
(C
o
n
ti
n
u
ed
)
A
u
th
o
r,
y
ea
r;
co
u
n
tr
y
S
tu
d
y
B
a
se
li
n
e
sa
m
p
le
A
n
x
ie
ty
m
ea
su
re
m
en
t
D
ia
b
et
es
in
ci
d
en
ce
M
ea
su
re
m
en
t
In
ci
d
en
t
d
ia
b
et
es
ca
se
s
S
ta
ti
st
ic
a
l
a
n
a
ly
si
s
C
o
n
fo
u
n
d
er
s
a
d
ju
st
ed
R
es
u
lt
s
M
ea
su
re
(c
u
t-
o
ff
p
o
in
ts
)
T
y
p
e
o
f
a
n
x
ie
ty
(l
en
g
th
ep
is
o
d
e)
S
o
ci
o
d
em
o
g
ra
p
h
ic
s
C
a
rd
io
-
m
et
a
b
o
li
c
a
n
d
/o
r
a
d
ip
o
si
ty
O
th
er
L
ea
st
a
d
ju
st
ed
M
o
st
a
d
ju
st
ed
M
il
le
r-
A
rc
h
ie
et
al
.,
2
0
1
4
[3
0
];
U
S
A
T
h
e
W
o
rl
d
T
ra
d
e
C
en
te
r
H
ea
lt
h
R
eg
is
tr
y
N
=
3
6
8
9
9
A
g
e:
1
8
+
y
ea
rs
W
it
h
in
ci
d
en
t
d
ia
b
et
es
S
ex
:
3
4
.6
%
fe
m
a
le
W
it
h
o
u
t
in
ci
d
en
t
d
ia
b
et
es
S
ex
:
3
8
.4
%
fe
m
a
le
9
/1
1
-s
p
ec
ifi
c
P
T
S
D
C
h
ec
k
li
st
(P
C
L
),
(P
T
S
D
≥
4
4
)
P
T
SD
sy
m
p
to
m
s
(p
a
st
m
o
n
th
)
2
1
4
3
in
ci
d
en
t
ca
se
s
(5
.8
%
)
F
o
ll
o
w
-u
p
:
9
y
ea
rs
L
o
g
is
ti
c
re
g
re
ss
io
n
S
ex
,
a
g
e,
ra
ce
/e
th
n
ic
it
y
,
ed
u
ca
ti
o
n
H
y
p
er
te
n
si
o
n
,
h
ig
h
ch
o
le
st
er
o
l,
B
M
I
O
R
1
.7
3
(1
.5
6
–1
.9
3
)
O
R
1
.2
8
(1
.1
4
–1
.4
4
)
P
 er
ez
-P
i~ n
a
r
et
al
.,
2
0
1
6
[3
5
];
U
K
A
ll
p
a
ti
en
ts
,
a
g
ed
≥
3
0
y
ea
rs
,
re
g
is
te
re
d
in
1
4
0
p
ri
m
ar
y
ca
re
p
ra
ct
ic
es
in
L
o
n
d
o
n
N
=
5
2
4
9
5
2
A
g
e:
3
0
+
y
ea
rs
(m
ea
n
4
5
.9

1
3
.9
y
ea
rs
)
S
ex
:
4
7
.1
%
fe
m
a
le
E
th
n
ic
it
y
:
4
1
.9
%
w
h
it
e
2
7
.6
%
S
o
u
th
A
si
a
n
1
7
.0
%
b
la
ck
6
.2
%
o
th
er
7
.3
%
u
n
k
n
o
w
n
A
n
x
ie
ty
R
ea
d
co
d
es
A
n
x
ie
ty
:
A
n
x
ie
ty
st
a
te
s,
p
h
o
b
ic
d
is
o
rd
er
s,
o
th
er
a
n
x
ie
ty
d
is
o
rd
er
s,
p
h
o
b
ic
a
n
x
ie
ty
d
is
o
rd
er
s,
g
en
er
a
li
ze
d
a
n
x
ie
ty
)
D
ia
b
et
es
re
a
d
co
d
es
3
1
9
4
2
in
ci
d
en
t
ca
se
s
(6
.3
%
)
F
o
ll
o
w
-u
p
:
1
0
y
ea
rs
C
o
x
re
g
re
ss
io
n
m
o
d
el
s,
h
a
za
rd
ra
ti
o
s
A
g
e,
g
en
d
er
,
et
h
n
ic
it
y
,
a
n
d
so
ci
a
l
d
ep
ri
v
at
io
n
–
A
n
ti
d
ep
re
ss
a
n
ts
,
a
n
ti
p
sy
ch
o
ti
cs
–
H
R
1
.1
4
(1
.0
8
,
1
.2
0
)
S
ch
er
re
r
et
al
.,
2
0
1
1
[3
1
];
U
S
A
N
a
ti
o
n
a
l
V
A
A
d
m
in
is
tr
a
ti
ve
D
a
ta
N
=
1
8
4
9
2
5
A
g
e:
2
5
-8
0
y
ea
rs
(m
ea
n
5
5
.6

1
3
.1
y
ea
rs
)
S
ex
:
9
.6
%
fe
m
a
le
E
th
n
ic
it
y
:
7
5
.5
%
w
h
it
e
2
0
%
n
o
n
-w
h
it
e
4
.5
%
u
n
k
n
o
w
n
IC
D
-9
co
d
es
P
T
SD
G
A
D
P
a
n
ic
O
th
er
a
n
x
ie
ty
D
ia
b
et
es
a
ss
es
se
d
b
y
IC
D
-9
-C
M
co
d
e
2
8
5
3
5
in
ci
d
en
t
ca
se
s
(1
5
.4
%
)
F
o
ll
o
w
-u
p
:
6
y
ea
rs
(A
)
C
o
x
p
ro
p
o
rt
io
n
a
l
h
a
za
rd
m
o
d
el
s
(B
)
N
u
m
b
er
o
f
ev
en
ts
A
g
e
B
M
I
(P
T
S
D
)
P
T
S
D
(G
A
D
)
P
T
SD
H
R
1
.2
5
(1
.2
1
–1
.2
9
)
G
A
D
H
R
1
.0
7
(1
.0
1
–1
.1
3
)
P
T
SD
H
R
1
.2
5
(1
.2
1
–1
.2
9
)
G
A
D
H
R
1
.0
9
(1
.0
6
–1
.1
2
)
S
h
ir
o
m
et
al
.,
2
0
1
0
[3
7
];
Is
ra
el
C
la
rl
it
h
ea
lt
h
se
rv
ic
es
d
a
ta
b
a
se
N
=
8
7
0
A
g
e:
1
8
–7
3
y
ea
rs
(m
ea
n
4
1
.7
0
y
ea
rs
)
S
ex
:
3
3
%
fe
m
a
le
C
o
rn
el
l
M
ed
ic
al
In
d
ex
:
U
n
cl
ea
r
h
o
w
th
is
w
a
s
sc
o
re
d
b
u
t
m
o
st
li
k
el
y
co
n
ti
n
u
o
u
s
(0
–5
)
A
n
x
ie
ty
sy
m
p
to
m
s
(h
o
w
th
ey
fe
el
m
o
st
o
f
th
e
ti
m
e)
IC
D
-9
co
d
es
cr
o
ss
-v
a
li
d
a
te
d
a
g
a
in
st
m
ed
ic
a
ti
o
n
u
se
fi
le
s
a
n
d
se
ru
m
a
n
al
y
si
s
o
f
H
b
A
1
c
fo
r
th
e
d
ia
g
n
o
si
s
o
f
d
ia
b
et
es
1
0
9
in
ci
d
en
t
ca
se
s
(1
2
.5
%
)
F
o
ll
o
w
-u
p
:
2
0
y
ea
rs
C
o
x
p
ro
p
o
rt
io
n
a
l
h
a
za
rd
s
re
g
re
ss
io
n
A
g
e,
se
x
,
ed
u
ca
ti
o
n
a
l
le
v
el
B
M
I,
ch
o
le
st
er
o
l,
tr
ig
ly
ce
ri
d
es
,
a
rt
er
ia
l
b
lo
o
d
p
re
ss
u
re
,
g
lu
co
se
S
m
o
k
in
g
,
ex
er
ci
se
,
a
lc
o
h
o
l
co
n
su
m
p
ti
o
n
,
v
ig
o
u
r,
d
ep
re
ss
iv
e
sy
m
p
to
m
s
–
H
R
1
.0
0
0
.7
8
–1
.2
6
8
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Investigating the longitudinal association between diabetes and anxiety  K. J. Smith et al.
T
a
b
le
1
(C
o
n
ti
n
u
ed
)
A
u
th
o
r,
y
ea
r;
co
u
n
tr
y
S
tu
d
y
B
a
se
li
n
e
sa
m
p
le
A
n
x
ie
ty
m
ea
su
re
m
en
t
D
ia
b
et
es
in
ci
d
en
ce
M
ea
su
re
m
en
t
In
ci
d
en
t
d
ia
b
et
es
ca
se
s
S
ta
ti
st
ic
a
l
a
n
a
ly
si
s
C
o
n
fo
u
n
d
er
s
a
d
ju
st
ed
R
es
u
lt
s
M
ea
su
re
(c
u
t-
o
ff
p
o
in
ts
)
T
y
p
e
o
f
a
n
x
ie
ty
(l
en
g
th
ep
is
o
d
e)
S
o
ci
o
d
em
o
g
ra
p
h
ic
s
C
a
rd
io
-
m
et
a
b
o
li
c
a
n
d
/o
r
a
d
ip
o
si
ty
O
th
er
L
ea
st
a
d
ju
st
ed
M
o
st
a
d
ju
st
ed
V
a
cc
ar
in
o
et
al
.,
2
0
1
4
[3
2
];
U
S
A
V
ie
tn
a
m
E
ra
T
w
in
R
eg
is
tr
y
N
=
4
3
4
0
A
g
e:
1
8
+
y
ea
rs
S
ex
:
0
%
fe
m
a
le
E
th
n
ic
it
y
:
9
0
.1
%
w
h
it
e
D
ia
g
n
o
st
ic
In
te
rv
ie
w
S
ch
ed
u
le
(D
IS
)
S
u
b
th
re
sh
o
ld
P
T
S
D
w
a
s
d
efi
n
ed
b
y
m
ee
ti
n
g
so
m
e,
b
u
t
n
o
t
a
ll
,
cr
it
er
ia
fo
r
P
T
S
D
P
T
S
D
(l
if
et
im
e)
S
el
f-
re
p
o
rt
ed
(d
o
ct
o
r
d
ia
g
n
o
si
s
a
n
d
m
ed
ic
a
ti
o
n
)
6
5
8
in
ci
d
en
t
ca
se
s
(1
5
.2
%
)
F
o
ll
o
w
-u
p
:
m
ed
ia
n
1
9
.4
y
ea
rs
M
u
lt
iv
a
ri
a
te
lo
g
is
ti
c
re
g
re
ss
io
n
A
g
e,
ra
ce
,
et
h
n
ic
it
y
,
m
a
ri
ta
l
st
a
tu
s,
ed
u
ca
ti
o
n
B
M
I,
h
y
p
er
te
n
si
o
n
,
h
y
p
er
ch
o
-
le
st
er
o
la
em
ia
B
ra
n
ch
o
f
se
rv
ic
e,
en
li
st
m
en
t
y
ea
r,
se
rv
ic
e
in
S
o
u
th
ea
st
A
si
a
,
a
n
d
m
il
it
a
ry
ra
n
k
a
t
en
li
st
m
en
t,
ci
g
ar
et
te
sm
o
k
in
g
,
a
lc
o
h
o
l
u
se
,
p
h
y
si
ca
l
a
ct
iv
it
y
,
h
is
to
ry
o
f
ca
rd
io
va
sc
u
la
r
d
is
ea
se
,
d
ep
re
ss
io
n
,
g
en
er
a
li
ze
d
a
n
x
ie
ty
d
is
o
rd
er
,
a
n
d
a
lc
o
h
o
l
o
r
d
ru
g
a
b
u
se
d
is
o
rd
er
Su
b
th
re
sh
o
ld
P
T
SD
O
R
1
.2
(0
.8
–1
.7
)
P
T
SD
O
R
1
.0
(0
.6
–1
.7
)
N
.B
.
a
d
ju
st
ed
fo
r
a
g
e
Su
b
th
re
sh
o
ld
P
T
SD
O
R
1
.2
(0
.9
–1
.5
)
P
T
SD
O
R
1
.2
(0
.9
–1
.7
)
D
ia
b
et
es
to
in
ci
d
en
t
a
n
x
ie
ty
E
n
g
u
m
et
al
.,
2
0
0
7
[3
4
];
N
o
rw
a
y
H
U
N
T
-1
(1
9
8
4
–
1
9
8
6
)
a
n
d
H
U
N
T
-2
(1
9
9
5
–1
9
9
7
)
N
=
3
7
2
9
1
A
g
e:
3
0
–8
9
y
ea
rs
A
n
x
io
u
s/
d
ep
re
ss
ed
gr
o
u
p
S
ex
:
5
9
.1
%
fe
m
a
le
N
o
n
-a
n
x
io
u
s/
d
ep
re
ss
ed
gr
o
u
p
5
1
.0
%
fe
m
a
le
S
el
f-
re
p
o
rt
(t
y
p
e
o
f
d
ia
b
et
es
d
et
er
m
in
ed
b
y
u
si
n
g
g
lu
ta
m
ic
a
ci
d
d
ec
a
rb
o
x
-
y
la
se
,
C
-p
ep
ti
d
e
te
st
s,
a
n
d
st
a
rt
o
f
in
su
li
n
tr
ea
tm
en
t)
B
a
se
li
n
e:
A
D
I
F
o
ll
o
w
-u
p
H
A
D
S
-A
:
>
8
a
n
x
ie
ty
A
D
I:
G
en
er
a
l
se
lf
-r
ep
o
rt
a
n
x
ie
ty
sy
m
p
to
m
s
H
A
D
S
-A
:
P
a
st
-w
ee
k
se
lf
-r
ep
o
rt
ed
a
n
x
ie
ty
sy
m
p
to
m
s
N
=
2
8
4
1
in
ci
d
en
t
ca
se
s
F
o
ll
o
w
-u
p
:
1
0
y
ea
rs
L
o
gi
st
ic
re
g
re
ss
io
n
A
g
e,
g
en
d
er
,
ed
u
ca
ti
o
n
a
l
le
v
el
,
a
n
d
m
a
ri
ta
l
st
a
tu
s
-
-
T
yp
e
1
d
ia
b
et
es
O
R
0
.4
7
(0
.1
5
–1
.5
1
)
T
yp
e
2
d
ia
b
et
es
O
R
0
.7
6
(0
.4
2
–1
.3
7
)
T
yp
e
1
d
ia
b
et
es
O
R
0
.5
0
(0
.1
6
-1
.6
1
)
T
yp
e
1
d
ia
b
et
es
O
R
0
.7
6
(0
.4
2
–1
.3
7
)
M
a
rr
ie
et
al
.,
2
0
1
6
[2
9
];
C
a
n
a
d
a
A
d
m
in
is
tr
a
ti
v
e
d
a
ta
fr
o
m
A
lb
er
ta
N
=
5
0
8
1
8
(9
6
2
4
p
er
so
n
s
w
it
h
M
S
,
a
n
d
4
1
1
9
4
m
a
tc
h
es
)
A
g
e:
m
ea
n
~
4
2
.8
y
ea
rs
M
S
ca
se
s
S
ex
:
6
8
.9
%
fe
m
a
le
C
o
n
tr
o
ls
S
ex
:
6
7
.0
%
fe
m
a
le
IC
D
-9
o
r
1
0
co
d
es
IC
D
co
d
es
fo
r
a
n
x
ie
ty
d
is
o
rd
er
s
A
n
x
ie
ty
d
is
o
rd
er
s
L
en
g
th
:
n
o
t
sp
ec
ifi
ed
.
N
o in
fo
rm
a
ti
o
n
in
ci
d
en
t
a
n
x
ie
ty
F
o
ll
o
w
-u
p
:
~
1
0
y
ea
rs
C
o
x
p
ro
p
o
rt
io
n
a
l
h
a
za
rd
s
m
o
d
el
s
A
g
e,
se
x
,
in
d
ex
y
ea
r
(f
o
r
M
S
),
S
E
S
–
H
y
p
er
te
n
si
o
n
,
is
ch
a
em
ic
h
ea
rt
d
is
ea
se
,
h
y
p
er
li
p
id
a
em
ia
,
lu
n
g
d
is
ea
se
,
fi
b
ro
m
ya
lg
ia
,
ep
il
ep
sy
,
in
fl
a
m
m
a
to
ry
b
o
w
el
d
is
ea
se
(p
h
y
si
ca
l
co
m
o
rb
id
it
ie
s
ti
m
e-
v
ar
y
in
g
)
-
C
o
m
b
in
ed
p
o
p
u
la
ti
o
n
s
H
R
1
.1
1
(0
.9
9
–1
.2
5
)
M
at
ch
ed
co
n
tr
o
ls
H
R
1
.0
9
(0
.9
5
–1
.2
4
)
M
S
p
o
p
u
la
ti
o
n
o
n
ly
H
R
1
.2
2
(0
.9
4
–1
.5
8
)
A
D
I,
A
n
x
ie
ty
a
n
d
D
ep
re
ss
io
n
In
v
en
to
ry
;
H
A
D
S
-A
:
H
o
sp
it
a
l
A
n
x
ie
ty
a
n
d
D
ep
re
ss
io
n
S
ca
le
;
G
A
D
,
ge
n
er
al
iz
ed
an
x
ie
ty
d
is
o
rd
er
;
H
R
,
h
a
za
rd
ra
ti
o
;
IC
D
,
In
te
rn
a
ti
o
n
a
l
S
ta
ti
st
ic
a
l
C
la
ss
ifi
ca
ti
o
n
o
f
D
is
ea
se
s
a
n
d
R
el
a
te
d
H
ea
lt
h
P
ro
b
le
m
s;
M
S
,
m
u
lt
ip
le
sc
le
ro
si
s;
O
R
,
o
d
d
s
ra
ti
o
;
P
C
L
-C
,
P
T
S
D
ch
ec
k
li
st
C
iv
il
ia
n
v
er
si
o
n
;
P
H
Q
,
P
a
ti
en
t
H
ea
lt
h
Q
u
es
ti
o
n
n
a
ir
e;
P
T
S
D
,
p
o
st
-t
ra
u
m
a
ti
c
st
re
ss
d
is
o
rd
er
;
R
R
,
ri
sk
ra
ti
o
;
V
A
:
V
et
er
a
n
s
A
ff
a
ir
s
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 9
Systematic Review or Meta-analysis DIABETICMedicine
Table 2 Quality assessment of included studies
Author, year
NOS score
(maximum 9)
ROBINS-I overall
risk of bias
Most important study limitations and strengths
(qualitative assessment)
Abraham et al., 2015 [22] 9 Low/moderate Limitations: Used self-report trait anxiety scale split into
data-driven quartiles rather than validated cut-offs being used.
Strengths: Large, representative multi-ethnic cohort.
Comprehensive diabetes assessment (excluded people possible
undiagnosed diabetes). Comprehensive set of confounders
controlled for.
Atlantis et al., 2012 [33] 5 Serious Limitations: Lack of confounder control. Short length of follow-up
and few people developed diabetes. Main analysis based on
10-point increase in anxiety scores (not a validated cut-off).
Strengths: Large population specifically sampled for anxiety
and depression. Event data for anxiety disorders based on
diagnostic interviews available.
Boyko et al., 2010 [23] 5 Moderate Limitations: Military population only so limited generalizability.
Fully adjusted analysis was a backwards multiple regression so
fully adjusted estimates of interest could not be included.
Self-report scales for anxiety (although applied diagnostic criteria)
and self-report diabetes.
Strengths: Large sample size.
Chien and Lin, 2016 [36] 8 Moderate Limitations: Administrative database (may underestimate anxiety
and diabetes). No control cardiometabolic confounders. No
crude estimate. Diagnostic codes included disorders no longer
considered anxiety disorders (e.g. PTSD).
Strengths: Large non-Western population.
Demmer et al., 2015 [24] 8 Moderate Limitations: Used self-report anxiety scale. Lack of control for
cardiometabolic abnormalities (other than BMI).
Strengths: Large representative population with long follow-up.
Comprehensive assessment of incident diabetes.
Desche^nes et al., 2016 [25] 6 Moderate Limitations: Oversampled people with depression and metabolic
abnormalities from pre-existing dataset not representative
population. Low diabetes incidence. Ethnically homogenous sample.
Strengths: Large sample. Stratification by prediabetes status.
Comprehensive set of confounders controlled for.
Engum et al., 2007 [34] 5 / Limitations: Different assessment baseline and follow-up anxiety.
No control cardiometabolic confounders. Self-report anxiety
and diabetes. No description missing data. Ascertainment bias
possibility (only one follow-up in 10 years).
Strengths: Large representative sample.
Edwards and Mezuk, 2012 [26] 6 Moderate/serious Limitations: Lack of transparency in describing follow-up data.
Self-report diabetes. No description time-frame for anxiety.
Relatively small number of participants with anxiety. Lack
of control for cardiometabolic abnormalities (other than BMI).
Strengths: Large representative sample, some ethnic diversity.
Used diagnostic interviews for anxiety.
Farvid et al., 2014 [27] 8 Moderate Limitations: Healthcare professional populations only so limited
generalizability. Self-report anxiety scale assessing personality
phobic anxiety rather than phobic anxiety disorder. Ethnically
homogenous sample.
Strengths: Results from three studies provided. Large samples
and long follow-ups. Comprehensive assessment of diabetes.
Khambaty et al., 2017 [28] 8 Moderate Limitations: Short anxiety screen rather than full anxiety scale
or diagnostic interview. Non-representative clinical population.
Strengths: Large population. Comprehensive assessment of diabetes.
Transparency in reporting. Ethnically diverse sample.
Marrie et al., 2016 [29] 7 Moderate/serious Limitations: Not a representative study so limited generalizability
(people with MS and matched controls). Administrative database
(may underestimate anxiety and diabetes). No control
cardiometabolic confounders.
Strengths: Large sample size.
Miller-Archie et al., 2014 [30] 8 Moderate Limitations: Not a representative sample (only people exposed
to 9/11 disaster). PTSD only assessed (no longer anxiety
disorder in DSM-V). PTSD and diabetes assessed with
self-report. Not all confounders measured at baseline.
Strengths: Large sample.
Perez-Pi~nar et al., 2016 [35] 8 Moderate/serious Limitations: Primary care database (may underestimate anxiety and
diabetes). No description time-frame for anxiety. Lack of control
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significant association. Scherrer et al. [31] found that veter-
ans with doctor-diagnosed PTSD at baseline had a 1.25 times
increased hazard of developing incident diabetes, an associ-
ation that remained significant after adjustment for BMI and
age. Boyko et al. [23] examined PTSD in a military popu-
lation using a validated scale and found those endorsing PTSD
symptoms had a 2.56 times increased odds of developing
incident diabetes over 3 years, an association that remained
significant after adjustment for sociodemographics and BMI.
They also found that panic and other anxiety also predicted
incident diabetes. Miller-Archie et al. [30] examined symp-
toms of PTSD in people exposed to a traumatic event and
found that high baseline PTSD symptoms were associated
with a 1.73 times increased odds of developing incident
diabetes, an association that remained significant after
controlling for sociodemographics and cardiometabolic
abnormalities.
One article included data from three studies conducted in
healthcare professionals and found that phobic anxiety
symptoms at baseline were associated with an increased
hazard of developing incident diabetes over 18–20 years in
all three studies [27]. However, the association in the study
that only included men (Healthcare Professionals Study) was
no longer significant after adjustment for confounders,
whereas the two studies in women (Nurses Health Studies I
and II) remained significant [27].
Of the four studies that did not provide unadjusted or
minimally adjusted estimates, three found a significant
association between baseline anxiety and incident diabetes
[28,35,36]. Chien and Lin [36] used data from a Taiwanese
insurance database to determine that diagnosed anxiety
disorders were associated with a 1.34 times increased risk of
developing incident diabetes over 5 years after adjusting for
sociodemographics. Khambaty et al. [28] measured anxiety
with a short screening scale in older adults and found that
after adjusting for sociodemographics, cardiometabolic
characteristics and smoking, those with anxiety had a
1.36 times increased hazard of incident diabetes over
10 years. Perez-Pi~nar et al. [35] used read codes in a
primary care database to determine that diagnosed anxiety
disorders were associated with a 1.14 times increased
hazard of developing diabetes over 10 years after adjusting
for sociodemographics and medication.
In total, three studies indicated there was no unadjusted or
minimally adjusted association between either trait anxiety
with incident diabetes [22], anxiety disorders with incident
diabetes [26] or PTSD symptoms with incident diabetes [32].
There was study heterogeneity in terms of follow-up,
measurement, population and analysis (Table 1). Study
follow-up ranged between 2 years [33] and 20 years
[27,37]. Studies with a shorter range of follow-up (2–
5 years) reported overall diabetes incidence rates of 0.01%
to 3.5% [23,25,33] compared with overall diabetes incidence
rates of 4.4% to 25.9% in studies with a follow-up of
10 years or more [22,24,26–28,32,35,37]. Types of anxiety
measurements included the assessment of non-specific anx-
iety symptoms, a composite of different anxiety disorders,
PTSD, phobic anxiety symptoms, panic, GAD and/or other
anxiety (Table 1). Anxiety was determined using a variety of
validated symptom scales [22–25,27,28,30,33,37], diagnos-
tic interviews [26,32,33] and examination of medical records
[31,35,36]. Most studies examined general anxiety or defined
Table 2 (Continued)
Author, year
NOS score
(maximum 9)
ROBINS-I overall
risk of bias
Most important study limitations and strengths
(qualitative assessment)
for cardiometabolic abnormalities. Unadjusted estimates
not available.
Strengths: Large ethnically diverse sample.
Scherrer et al., 2011 [31] 5 Serious Limitations: Veteran population only so limited generalizability.
Administrative database (may underestimate anxiety and diabetes).
Limited adjustment for confounders.
Strengths: Large sample size
Shirom et al., 2010 [37] 8 Moderate Limitations: Self-report anxiety symptoms. Women
under-represented in sample and people with high SES
overrepresented (sample not generalizable). PTSD only assessed
(no longer anxiety disorder in DSM-V).
Strengths: Good sized sample. Comprehensive set of confounders
controlled for.
Vaccarino et al., 2014 [32] 7 Low/moderate Limitations: Veteran population only so limited generalizability.
Self-report diabetes. Ethnically homogenous sample.
Strengths: Large sample. Used diagnostic interviews for anxiety.
Comprehensive set of confounders controlled for.
NOS, Newcastle–Ottawa Scale. For this scale studies were ranked out of nine stars for selection bias, information bias, comparability and
quality.
ROBINS-I (Risk of Bias in Non-randomised studies of Interventions). For this scale studies were ranked for bias across six domains
(confounding, selection of participants, classification of intervention, missing data, measurement of outcomes, reporting of results).
Qualitative assessment: the two study reviewers independently assessed the main strengths and limitations of the included studies.
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anxiety or anxiety disorders using DSM-V criteria [22,24–
28,33,35,37]. However, three studies included anxiety dis-
orders as defined by DSM-IV [23,31,36] and two studies only
provided estimates for PTSD [30,32].
All studies excluded people with diagnosed diabetes at
baseline. Four studies also excluded people with high levels
of blood glucose t baseline and assessed incident diabetes
using blood glucose levels [22,28,33,37]. One study also
explicitly accounted for prediabetes in their analysis [25].
The remaining nine studies relied on self-report or medical
records, and therefore undiagnosed diabetes could be an
issue with these studies (Table 1). Notably, most incident
cases included in this direction of causality would have
assessed incident Type 2 diabetes as studies were conducted
in adult populations (Table 1).
There were also differences in the populations studied
(Table 1). Three studies were conducted in veteran or
military populations [23,31,32], one study examined health-
care professionals [27], one study was conducted in people
exposed to the 9/11 attacks in New York [30], two studies
sampled people from a health insurance database [36,37],
two studies sampled people from primary care [28,35], one
study sampled a mixture of clinical and community popu-
lations [33] and the remaining four studies were sampled
from the community [22,24–26]. Furthermore, two studies
oversampled people on the basis of anxiety and/or depression
at baseline [25,33].
Finally, there were differences in the analyses employed by
researchers, with six studies calculating ORs, two studies
calculating risk ratios (RRs) and six studies calculating
hazards ratios (HRs) (Table 1). Furthermore, one study did
not control for any confounders [33], one study only
controlled for age and BMI [31] and one study only
controlled for sociodemographic confounders [36], whereas
most studies controlled for a range of sociodemographic,
cardiometabolic and other confounders [22,24–28,30,32,37].
Diabetes to incident anxiety
Only two studies examined the association between diabetes
and incident anxiety (Table 1). Both studies had moderate to
serious quality issues (Table 2). The first study by Engum
et al. [34] found no association between either Type 1 or
Type 2 diabetes and incident anxiety symptoms over
10 years in a Norwegian population sample. Although the
study included a large and representative sample, they used a
different measure for anxiety at baseline and follow-up,
thereby limiting inferences about incidence (Table 1). The
second study by Marrie et al. [29] provided only fully
adjusted estimates and found no association between
diabetes and incident anxiety in an administrative database
over 10 years of follow-up. However, generalizability was
limited by the fact that participants were sampled based on a
diagnosis of multiple sclerosis or being a matched-control
for multiple sclerosis participants. Both studies found
no association from diabetes to incident anxiety, however
due to study quality and generalizability, inferences are
limited.
Implications of study review for meta-analysis
Because of the small number of studies for the direction of
association from diabetes to incident anxiety, we could not
move forward with a meta-analysis for this direction.
However, we had sufficient data to examine the direction
of association from anxiety to incident diabetes. Owing to
differences in analysis (Table 1) we opted to combine all
studies for a least adjusted estimate using ORs or raw event
data (either calculated from data provided in the paper or by
contacting study authors) that were then converted to ORs
(Table S3). Furthermore, as one paper had analysed results
from three studies separately [27], we opted to enter each
study independently into the meta-analysis. Owing to study
heterogeneity, we then ran a series of sensitivity analyses on
our results to determine whether those sources of hetero-
geneity we identified in our review would have any impact on
the combined estimate. We opted to run a series of analyses
stratified by definition of anxiety given that the current
definition of anxiety disorders no longer includes disorders
such as PTSD and OCD (DSM-V), which were previously
classified as anxiety disorders (DSM-IV). We also examined
most-adjusted data, but these analyses were stratified by the
estimate provided by the authors (i.e. OR or HR).
Meta-analysis
Results from 15 studies across 13 publications were entered
into a random-effects meta-analysis (Fig. 2). Unadjusted or
age-adjusted ORs and raw event data were combined
(Table S3). We were unable to access raw data for one study
[37], however all other studies were included.
The pooled OR from the 15 studies was 1.47 (1.23–1.75).
However, study heterogeneity was high (I2 = 98.13) and the
funnel plot (Fig. S1) and Egger’s test (P = 0.05) indicated the
presence of publication bias. In analyses stratified by anxiety
assessment type, diabetes assessment type, and most other
general sensitivity analyses, the estimate mostly remained
stable (Table 3). However, there was no significant associ-
ation between anxiety and incident diabetes in sensitivity
analyses that combined only studies that assessed baseline
diagnosed anxiety disorders (as defined by DSM-V criteria),
studies that had some serious risk of bias, and studies that
provided stratified estimates for men.
When we examined the most adjusted associations strat-
ified by type of analysis, all estimates indicated a significant
association between baseline anxiety with incident diabetes
(Table 4). The eight studies that calculated an adjusted HR
estimate had a combined estimate of HR 1.14 (1.08–1.21)
(for forest plot see Fig. S2). Study heterogeneity was high for
these studies (I2 = 71.94), however there was little evidence
of publication bias (Egger’s test, P = 0.38; see Fig. S1 for
funnel plot). The five studies that calculated an adjusted OR
had a combined estimate of OR 1.64 (1.13–2.39) (for forest
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plot see Fig. S2). Study heterogeneity was high (I2 = 84.13),
however Egger’s test was non-significant (P = 0.20; see
Fig. S1 for funnel plot). Finally, the two studies that
calculated an adjusted RR had a combined estimate of RR
1.34 (1.27 1.41) (for forest plot see Fig. S2). Study hetero-
geneity was low for these studies (I2 = 0).
We ran a series of sensitivity analyses for the HR and OR
estimates (Table 4). The HR estimate remained significant
except when we only examined studies that had a low–
moderate risk of bias. The OR estimate was reduced to non-
significance when we removed the largest study [23], only
assessed low–moderate quality studies, and only included
studies that had controlled for a variety of sociodemo-
graphic, cardiometabolic/adiposity and lifestyle factors [25,
26]. We could not run sensitivity analyses for the risk ratio
estimate as only two studies were included.
Discussion
The results from this systematic review and meta-analysis
indicate that anxiety symptoms and disorders (as defined by
both DSM-IV and DSM-V criteria) are associated with an
increased risk of developing incident diabetes. Furthermore,
our results indicate that the association between anxiety and
incident diabetes persists even after adjusting for a range of
sociodemographic, cardiometabolic and adiposity-related
confounders. However, the two studies that examined the
direction of association from diabetes to incident anxiety
found no evidence of an association, although inferences are
limited by the small number of studies and quality issues.
Anxiety to diabetes
Previous work has hypothesized that anxiety could lead to an
increased risk of diabetes [19], however, to the best of our
knowledge, this is the first synthesis that confirms anxiety as
a risk factor for incident diabetes.
The association between anxiety and an increased risk of
incident diabetes is likely due to a nuanced and complex
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-value P-value
Abraham et al. [22] 1.366 1.136 1.643 3.315 0.001
Atlantis et al. [33] 3.621 1.353 9.688 2.563 0.010
Boyko et al., [23] 2.542 1.942 3.327 6.793 0.000
Chien and Lin [36] 1.937 1.843 2.036 26.108 0.000
Demmer et al. [24] 1.002 0.789 1.272 0.015 0.988
Deschênes et al. [25] 6.886 3.559 13.321 5.731 0.000
Edwards and Mezuk [26] 1.210 0.721 2.032 0.721 0.471
Farvid et al. [27] NHS 1.235 1.152 1.324 5.953 0.000
Farvid et al. [27] NHS II 1.454 1.333 1.587 8.414 0.000
Farvid et al. [27] HPFS 0.966 0.802 1.162 -0.371 0.711
Khambaty et al. [28] 1.353 1.116 1.642 3.068 0.002
Miller-Archie et al. [30] 1.730 1.555 1.924 10.095 0.000
Pérez-Piñar et al [35] 1.338 1.272 1.408 11.261 0.000
Scherrer et al. [31] 0.992 0.970 1.015 -0.694 0.487
Vaccarino et al. [32] 1.000 0.594 1.683 0.000 1.000
1.469 1.233 1.751 4.302 0.000
0.1 0.2 0.5 1 2 5 10
Lower Higher
FIGURE 2 Forest plot of least-adjusted association between baseline anxiety and incident diabetes
Table 3 Sensitivity analysis and funnel plot for least-adjusted analysis
Odds ratio I2
All studies 1.47 (1.23–1.74) 98.13
Minus largest study
(Perez-Pi~nar et al. [35])
1.49 (1.22–1.82) 98.20
Minus most significant study
(Desche^nes et al. [25])
1.38 (1.61–1.65) 98.1
Low-moderate risk of bias studies 1.58 (1.53–1.64) 94.8
Some serious risk of bias studies 1.25 (0.93–1.68) 86.7
Follow-up 5 years or less 1.96 (1.87–2.06) 82.5
Follow-up 10 years or more 1.28 (1.24–1.33) 78.7
Only including anxiety/anxiety
disorder as defined in DSM-V
1.36 (1.17–1.60) 94.7
Anxiety disorders (DSM-V) 1.24 (0.88–1.74) 97.6
Anxiety symptoms (DSM-V) 1.43 (1.22–1.67) 86.7
PTSD only 1.51 (1.07–2.13) 95.9
Anxiety symptoms (with PTSD) 1.46 (1.28–1.71) 89.5
Studies where people with
possible undiagnosed
diabetes at baseline excluded.
1.42 (1.15–1.76) 46.5
Community population 1.86 (1.14–3.04) 88.0
Men 0.93 (0.79–1.09) 0
Women 1.35 (1.17–1.55) 76.1
DSM-V anxiety disorders include: generalized anxiety disorder
(GAD), panic, phobia. However, they no longer include post-
traumatic stress disorder (PTSD) and obsessive–compulsive
disorder (OCD) which were classified as anxiety disorders until
2013. For those studies only including DSM-V anxiety disor-
ders or anxiety we excluded PTSD from the combined estimate
for Boyko et al. [23] and excluded PTSD from the combined
estimate for Scherrer et al. [31]. Anxiety disorders (DSM-V)
comprises only those studies where a diagnosis of anxiety
disorders as defined by DSM-V was included (thus Chien and
Lin [36] were excluded as they combined PTSD and OCD in
their anxiety disorder estimate).
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relationship between anxiety and other risk factors for
diabetes. For example, anxiety is often comorbid with other
psychiatric disorders shown to be associated with diabetes
risk such as depression [26,38]. Thus, it is possible that the
association between anxiety and diabetes could be driven, in
part, by the comorbidity of anxiety with other psychological
disorders such as depression [39]. However, where studies
adjusted for depression [22,26,32], the inclusion of depres-
sion into the statistical model did not substantially affect
estimates. Furthermore, anxiety is associated with some
behavioural risk factors that are linked with diabetes risk
factors such as unhealthy lifestyle [12], sleep disturbance [13]
and obesity [10]. Anxiety is also linked with various
biological changes that have been shown to increase the risk
of diabetes such as inflammation [40] and cardiometabolic
abnormalities [11].
Although results from this analysis do not provide us with
information on how anxiety is linked with an increased risk
of incident diabetes, they do indicate that anxiety is an
independent risk factor for diabetes even when taking
confounders into account. However, more work is needed
on understanding pathways of how anxiety might lead to
diabetes.
Diabetes to anxiety
Results from this review indicate that more research is
needed on the direction of association from diabetes to
anxiety because only two studies were eligible for inclusion
in this review. Neither study that examined diabetes as a risk
factor for incident anxiety identified a significant association.
Despite this, other work we identified that was not eligible
for inclusion in this review did indicate a possible associa-
tion. Cooper et al. [41] found that young people with Type 1
diabetes (average age of 9 years at baseline) had a 2.5 times
increased hazard of developing incident anxiety over
26 years. Furthermore, Huang et al. [38] found a higher
annual incidence of people with diabetes being diagnosed
with an anxiety disorder over 5 years using data for nearly
1 million people from a Taiwanese insurance database.
However, this study was not included because the lowest
baseline age was 15 years. In addition, Hasan et al. [42]
Table 4 Sensitivity analyses and funnel plots for most-adjusted meta-analysis anxiety to diabetes stratified by analysis type
Hazard ratio Odds ratio Risk ratio
All studies 1.14 (1.08–1.21) 1.64 (1.13–2.39) 1.34 (1.27–1.41)
Minus largest study 1.12 (1.03–1.23) 1.48 (0.99–2.20) –
Minus most significant study 1.13 (1.06–1.20) 1.42 (1.03–1.95) –
Low–moderate risk of bias studies 1.13 (0.99–1.28) 1.81 (1.19–2.75) –
Some serious risk of bias studies 1.15 (1.13–1.18) Insufficient data (only
Edwards and Mezuk [26])
–
Follow up 5 years or less No studies 3.09 (1.41–6.76) –
Follow up 10 years or more 1.14 (1.04–1.24) 1.15 (0.85–1.56) –
Only including anxiety/anxiety
disorder as in DSM-V
1.14 (1.09–1.20) 2.06 (1.46–2.91) –
Anxiety disorder (DSM-V) 1.15 (1.13–1.18) Insufficient data (only
Edwards and Mezuk [26])
–
PTSD only Insufficient data (only
Scherrer et al. [31])
1.47 (1.06–2.03) –
Anxiety disorder (DSM-IV) 1.15 (1.13–1.18) Insufficient data (only
Edwards and Mezuk [26])
–
Anxiety symptoms 1.16 (1.13–1.18) 1.81 (1.19–2.75) –
Studies where people with possible
undiagnosed diabetes at baseline excluded
1.16 (1.13–1.18) No studies –
Studies where people with possible
undiagnosed diabetes at baseline not excluded
1.13 (1.07–1.21) All studies –
Outcome self-report diabetes or doctor diagnosis 1.13 (1.07–1.21) All studies –
Outcome diabetes validated with blood glucose levels 1.16 (1.13–1.18) No studies –
Community population Insufficient data (only
Abraham et al. [22])
1.89 (1.15–3.11) –
Controlled for sociodemographic and
cardiometabolic/adiposity
1.16 (1.11–1.21) 1.83 (1.12–2.98) –
Controlled for sociodemographic,
cardiometabolic/adiposity and lifestyle
1.15 (1.06–1.25) 2.21 (0.45–10.86) –
The following studies calculated hazards ratios: Abraham et al. [22], Farvid et al. [27], Khambaty et al. [28], Perez-Pi~nar et al. [35], Scherrer
et al. [31] and Shirom et al. [37].
The following studies calculated odds ratios: Boyko et al. [23], Desche^nes et al. [25], Edwards and Mezuk [26], Miller-Archie et al. [30] and
Vaccarino et al. [32].
The following studies calculated risk ratios: Chien and Lin [36] and Demmer et al. [24].
DSM-V anxiety disorders include: Generalized anxiety disorder (GAD), panic, phobia. However, they no longer include PTSD and OCD
which were classified as anxiety disorders until 2013. DSM-IV anxiety disorders include: GAD, panic, phobia, PTSD, OCD.
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found that diabetes was associated with a 2.6 times increased
likelihood of having a current anxiety disorder after 6 years
in Australian women (although they did not explicitly
remove anxiety at baseline). This work indicates that there
is a possibility that diabetes could lead to incident anxiety,
although exclusion criteria for our study precluded the
inclusion of many of these studies. Our work also indicates a
need for more research to explicitly examine whether
diabetes could lead to incident anxiety. Future work exam-
ining this direction of causation needs to be mindful of
possible generalizability and bias issues. For example, ascer-
tainment bias is more likely to be an issue with studies
examining incident anxiety than incident diabetes as anxiety
is more likely to have a diverse life course [43], which could
limit the likelihood of capturing an event. Furthermore, as
anxiety disorder tends to occur in adolescence or early
adulthood [44] the approach taken by Cooper et al. [41]
following people up from a younger age may better allow
us to make inferences on diabetes as a cause of incident
anxiety.
Clinical implications
This work adds to the body of evidence suggesting that poor
mental health is an important diabetes risk factor. Previous
work has found evidence that depression [45], PTSD [46]
and stress [19] can increase a person’s risk of developing
diabetes. This is likely a complex association via various and
likely interacting pathways. However, screening for and
integrating treatment for mental illness into diabetes preven-
tion programs could be important for helping to reduce the
increasing prevalence of diabetes.
Despite work from this review indicating that diabetes may
not be associated with an increased risk of incident anxiety,
there is still evidence that anxiety is an important comor-
bidity to consider in people with diabetes. Anxiety is
associated with poorer outcomes in people with diabetes
such as poorer glycaemic control [47], worsened functioning
[48] and increased diabetes complications [49]. As such, it is
important for care providers to integrate the screening and
treatment of mental health conditions such as anxiety into
diabetes care [50].
Strengths and limitations
There are limitations that must be acknowledged within this
review. First, there were indications that publication bias
may be an issue with this review and there was also notable
theoretical and statistical heterogeneity evident. Therefore,
results should be interpreted with caution. There were
differences in anxiety assessment, diabetes assessment, pop-
ulations studied and analyses conducted. However, we were
mindful of this limitation in our presentation and analysis.
We also only screened studies in French and English meaning
there could also be language bias present. Furthermore,
setting our inclusion age to 16 years meant that we had to
exclude some studies that provided compelling evidence on
the longitudinal relationship between anxiety and diabetes
(e.g. Cooper et al. [41]). In addition, there are also possibly
issues with only examining anxiety ‘cases’. There is a
possibility that below-threshold anxiety symptoms could
also lead to an increased risk of incident diabetes, however,
we were unable to determine this using data from the
included studies. Therefore, future work could examine how
below-threshold anxiety symptoms are associated longitudi-
nally with diabetes.
There are also limitations with examining both Type 1 and
Type 2 diabetes when determining longitudinal associations
between anxiety and diabetes. Those studies that examined
anxiety as a cause of incident diabetes are more likely to
capture people with Type 2 diabetes due to the earlier onset
of Type 1 diabetes. However, those studies that examined
diabetes as a cause of incident anxiety are arguably better
conducted in people with Type 1 diabetes as they could be
followed up from a younger age allowing us to better capture
first cases of anxiety. It is feasible that the best way to
determine causality between diabetes and anxiety would be
to take a life course approach to determine the incidence of
anxiety and/or diabetes while taking the date of diabetes
diagnosis into account. Future work could also stratify
analyses by diabetes type.
However, despite these limitations there are several
strengths to the present review. To the best of our knowl-
edge, this is the first synthesis to systematically investigate the
longitudinal association between anxiety and diabetes in a
large number of databases. Furthermore, we undertook a
comprehensive quality assessment and heterogeneity assess-
ments to determine the stability of estimates and potential
sources of differences in results.
Conclusions
Work from this analysis indicates that anxiety may be a risk
factor for incident diabetes. However, heterogeneity
between studies and evidence of publication bias suggest
that results should be interpreted with caution. Further-
more, there was limited evidence that investigated the
direction of association from diabetes to incident anxiety
indicating the need for future work to investigate this
direction of causality.
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